Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial
Liping Yang(Xinjiang Normal University), Kezheng Wang(Harbin Medical University), Wenzhi Wang(Harbin Medical University), Abiyasi Nanding(Harbin Medical University), Wei Guo(Army Medical University), Xing Wang Gao(Harbin Medical University), Da‐Yong Hou(Harbin Medical University), Liang Cheng(Brown University), Yue Zhao(Jackson Laboratory), Fan Jia(Harbin Medical University), Menglu Wang(Beijing University of Chinese Medicine), Yuchao Xu(University of South China), Hongchao Ding(Harbin Medical University), Hongxue Meng(Harbin Medical University), Wei Liu(Chinese Academy of Sciences), Xinyue Yang(Harbin Medical University)
European Journal of Nuclear Medicine and Molecular Imaging
December 16, 2024
Cited by 15
Related Papers
LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment
|Nature Communications|2018|525
Precise nanomedicine for intelligent therapy of cancer
|Science China Chemistry|2018|413
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
|Modern Pathology|2017|404
Polydopamine Spheres as Active Templates for Convenient Synthesis of Various Nanostructures
|Small|2012|356
High–rate electrochemical capacitors from highly graphitic carbon–tipped manganese oxide/mesoporous carbon/manganese oxide hybrid nanowires
|Energy & Environmental Science|2011|351